Skip to main content

T Cell Lymphoma clinical trials at UC Irvine

2 in progress, 0 open to eligible people

Showing trials for
  • A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

    Sorry, in progress, not accepting new patients

    This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL).

    Irvine, California and other locations

  • Mogamulizumab Q4week Dosing in Participants With R/R CTCL

    Sorry, not currently recruiting here

    This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

    Irvine, California and other locations

Last updated: